Can lenvatinib cause fatal tumour lysis syndrome?

Yes, lenvatinib can cause fatal tumour lysis syndrome; risk factors include high tumour burden, pre-existing renal impairment and dehydration, and patients with these risk factors should be monitored closely, treated as clinically indicated and considered for prophylactic hydration.